The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 1.20
U.S. and SEER Death Rates by Primary Cancer Site and Race/Ethnicity, 2013-2017
Cancer Site | Sex | Total United Statesa | SEER 21 Areasa b | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | White | Black | AI/AKc | APId | Hispanice | W-NHispe | Total | White | Black | AI/AKc | APId | Hispanice | W-NHispe | ||
All Sites | Both Sexes | 158.3 | 159.0 | 181.7 | 144.2 | 98.9 | 112.3 | 162.9 | 151.9 | 155.4 | 170.3 | 123.7 | 102.4 | 112.4 | 159.6 |
Male | 189.5 | 189.6 | 227.3 | 173.1 | 117.3 | 136.2 | 193.8 | 180.5 | 183.6 | 211.3 | 149.5 | 122.7 | 134.9 | 188.1 | |
Female | 135.7 | 136.4 | 153.4 | 123.0 | 85.6 | 95.5 | 139.9 | 131.7 | 135.1 | 145.4 | 104.8 | 87.7 | 97.0 | 138.9 | |
Oral Cavity & Pharynx | Both Sexes | 2.5 | 2.5 | 2.7 | 2.2 | 2.0 | 1.5 | 2.6 | 2.4 | 2.4 | 2.5 | 1.8 | 2.1 | 1.6 | 2.5 |
Male | 3.9 | 3.9 | 4.5 | 3.5 | 3.1 | 2.4 | 4.0 | 3.7 | 3.8 | 4.0 | 3.2 | 3.3 | 2.5 | 3.9 | |
Female | 1.3 | 1.4 | 1.3 | 1.1 | 1.1 | 0.8 | 1.4 | 1.3 | 1.3 | 1.3 | - | 1.2 | 0.8 | 1.4 | |
Esophagus | Both Sexes | 3.9 | 4.2 | 3.2 | 3.4 | 1.6 | 2.0 | 4.4 | 3.6 | 4.0 | 3.0 | 3.0 | 1.6 | 2.1 | 4.2 |
Male | 7.0 | 7.4 | 5.3 | 6.2 | 2.8 | 3.7 | 7.8 | 6.5 | 7.0 | 5.0 | 4.9 | 2.9 | 3.8 | 7.5 | |
Female | 1.4 | 1.4 | 1.6 | 1.3 | 0.7 | 0.7 | 1.5 | 1.4 | 1.4 | 1.5 | 1.4 | 0.6 | 0.8 | 1.5 | |
Stomach | Both Sexes | 3.1 | 2.7 | 5.3 | 4.8 | 5.2 | 5.0 | 2.3 | 3.5 | 3.0 | 5.2 | 5.5 | 5.4 | 5.4 | 2.5 |
Male | 4.1 | 3.6 | 7.8 | 6.3 | 6.7 | 6.4 | 3.2 | 4.7 | 4.1 | 7.7 | 7.4 | 7.1 | 6.8 | 3.5 | |
Female | 2.2 | 1.9 | 3.6 | 3.6 | 4.1 | 4.0 | 1.6 | 2.5 | 2.2 | 3.5 | 3.9 | 4.2 | 4.4 | 1.7 | |
Colon & Rectum | Both Sexes | 13.9 | 13.6 | 18.5 | 15.8 | 9.6 | 11.1 | 13.8 | 13.4 | 13.3 | 17.2 | 14.7 | 10.0 | 10.8 | 13.4 |
Male | 16.6 | 16.2 | 23.2 | 19.4 | 11.5 | 14.2 | 16.3 | 15.8 | 15.6 | 21.3 | 17.3 | 12.2 | 13.7 | 15.7 | |
Female | 11.8 | 11.5 | 15.2 | 13.0 | 8.1 | 8.7 | 11.7 | 11.4 | 11.3 | 14.3 | 12.7 | 8.3 | 8.7 | 11.6 | |
Liver & Intrahepatic Bile Duct | Both Sexes | 6.6 | 6.2 | 8.4 | 10.6 | 9.1 | 9.3 | 5.8 | 6.8 | 6.3 | 8.0 | 9.2 | 9.3 | 9.5 | 5.7 |
Male | 9.6 | 9.0 | 13.2 | 14.8 | 13.5 | 13.3 | 8.4 | 10.0 | 9.2 | 12.7 | 12.2 | 13.9 | 13.6 | 8.3 | |
Female | 4.0 | 3.8 | 4.8 | 7.1 | 5.6 | 6.0 | 3.5 | 4.1 | 3.9 | 4.6 | 6.5 | 5.6 | 6.2 | 3.5 | |
Pancreas | Both Sexes | 11.0 | 10.9 | 13.3 | 8.9 | 7.6 | 8.5 | 11.1 | 10.9 | 11.1 | 12.3 | 7.7 | 8.0 | 8.6 | 11.3 |
Male | 12.7 | 12.7 | 14.9 | 10.3 | 8.2 | 9.4 | 13.0 | 12.4 | 12.7 | 13.9 | 9.4 | 8.8 | 9.4 | 13.0 | |
Female | 9.6 | 9.4 | 12.0 | 7.8 | 7.1 | 7.8 | 9.6 | 9.6 | 9.7 | 11.2 | 6.3 | 7.5 | 7.9 | 9.8 | |
Larynx | Both Sexes | 1.0 | 0.9 | 1.6 | 0.9 | 0.3 | 0.7 | 1.0 | 0.9 | 0.9 | 1.4 | 0.6 | 0.3 | 0.6 | 0.9 |
Male | 1.7 | 1.7 | 3.0 | 1.7 | 0.6 | 1.4 | 1.7 | 1.5 | 1.5 | 2.7 | 1.3 | 0.6 | 1.3 | 1.5 | |
Female | 0.4 | 0.4 | 0.5 | - | 0.1 | 0.1 | 0.4 | 0.3 | 0.3 | 0.5 | - | 0.1 | 0.1 | 0.4 | |
Lung & Bronchus | Both Sexes | 40.2 | 41.0 | 42.3 | 33.4 | 22.2 | 17.6 | 43.4 | 36.1 | 37.4 | 37.8 | 24.1 | 23.0 | 16.6 | 40.2 |
Male | 49.3 | 49.4 | 58.8 | 40.1 | 29.3 | 24.2 | 51.8 | 43.6 | 44.1 | 52.1 | 31.0 | 31.1 | 22.2 | 46.8 | |
Female | 33.2 | 34.5 | 31.1 | 28.4 | 16.9 | 12.7 | 36.8 | 30.4 | 32.4 | 28.3 | 18.9 | 16.9 | 12.6 | 35.1 | |
Melanoma of the Skin | Both Sexes | 2.4 | 2.8 | 0.3 | 0.7 | 0.3 | 0.7 | 3.0 | 2.2 | 2.7 | 0.3 | 0.6 | 0.3 | 0.6 | 3.1 |
Male | 3.5 | 4.1 | 0.4 | 1.0 | 0.4 | 0.9 | 4.5 | 3.3 | 4.0 | 0.4 | - | 0.4 | 0.9 | 4.5 | |
Female | 1.5 | 1.7 | 0.3 | 0.5 | 0.3 | 0.5 | 1.9 | 1.4 | 1.7 | 0.2 | - | 0.3 | 0.5 | 1.9 | |
Breast | Female | 20.3 | 19.8 | 27.6 | 14.6 | 11.4 | 14.0 | 20.3 | 19.9 | 19.9 | 26.7 | 13.3 | 12.1 | 14.1 | 20.5 |
Cervix | Female | 2.3 | 2.2 | 3.4 | 2.5 | 1.8 | 2.6 | 2.1 | 2.1 | 2.0 | 3.2 | 2.0 | 1.8 | 2.5 | 1.9 |
Corpus & Uterus, NOS | Female | 4.8 | 4.5 | 8.6 | 3.4 | 3.2 | 4.0 | 4.5 | 5.1 | 4.8 | 8.7 | 3.1 | 3.3 | 4.2 | 4.7 |
Ovary | Female | 6.9 | 7.1 | 6.0 | 6.3 | 4.4 | 5.2 | 7.3 | 7.0 | 7.4 | 5.9 | 5.1 | 4.5 | 5.4 | 7.6 |
Prostate | Male | 19.1 | 17.9 | 37.9 | 18.7 | 8.6 | 15.8 | 18.0 | 19.3 | 18.6 | 36.9 | 16.2 | 9.0 | 16.6 | 18.7 |
Testis | Male | 0.3 | 0.3 | 0.1 | 0.4 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 0.1 | - | 0.1 | 0.3 | 0.3 |
Urinary Bladder | Both Sexes | 4.4 | 4.6 | 3.5 | 2.7 | 1.7 | 2.3 | 4.8 | 4.3 | 4.6 | 3.4 | 2.8 | 1.8 | 2.3 | 4.9 |
Male | 7.5 | 8.0 | 5.3 | 4.2 | 2.8 | 3.9 | 8.3 | 7.3 | 8.0 | 5.1 | 4.1 | 3.0 | 3.8 | 8.5 | |
Female | 2.1 | 2.2 | 2.4 | 1.7 | 0.9 | 1.3 | 2.3 | 2.1 | 2.2 | 2.4 | 1.8 | 0.9 | 1.3 | 2.4 | |
Kidney & Renal Pelvis | Both Sexes | 3.7 | 3.8 | 3.6 | 5.5 | 1.7 | 3.5 | 3.8 | 3.4 | 3.6 | 3.1 | 4.6 | 1.9 | 3.2 | 3.6 |
Male | 5.4 | 5.6 | 5.4 | 8.2 | 2.6 | 5.0 | 5.6 | 5.1 | 5.3 | 5.0 | 6.6 | 2.8 | 4.6 | 5.3 | |
Female | 2.3 | 2.4 | 2.2 | 3.4 | 1.1 | 2.2 | 2.4 | 2.1 | 2.3 | 1.8 | 3.1 | 1.2 | 2.1 | 2.3 | |
Brain & Nervous System | Both Sexes | 4.4 | 4.8 | 2.6 | 2.5 | 2.2 | 3.0 | 5.1 | 4.3 | 4.8 | 2.5 | 2.3 | 2.3 | 3.0 | 5.1 |
Male | 5.4 | 5.8 | 3.2 | 2.8 | 2.6 | 3.5 | 6.1 | 5.3 | 5.9 | 3.1 | 2.8 | 2.6 | 3.6 | 6.2 | |
Female | 3.6 | 3.9 | 2.2 | 2.4 | 1.9 | 2.6 | 4.1 | 3.5 | 3.9 | 2.0 | 1.9 | 2.0 | 2.6 | 4.1 | |
Thyroid | Both Sexes | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 | - | 0.6 | 0.7 | 0.5 |
Male | 0.5 | 0.5 | 0.4 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.4 | - | 0.5 | 0.7 | 0.6 | |
Female | 0.5 | 0.5 | 0.6 | 0.4 | 0.7 | 0.7 | 0.5 | 0.6 | 0.5 | 0.5 | - | 0.7 | 0.7 | 0.5 | |
Hodgkin Lymphoma | Both Sexes | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | 0.4 | 0.3 | 0.3 | 0.3 | 0.2 | - | 0.2 | 0.4 | 0.3 |
Male | 0.4 | 0.4 | 0.3 | - | 0.2 | 0.5 | 0.4 | 0.4 | 0.4 | 0.3 | - | 0.2 | 0.5 | 0.4 | |
Female | 0.2 | 0.2 | 0.2 | - | 0.1 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | - | 0.1 | 0.3 | 0.2 | |
Non-Hodgkin Lymphoma | Both Sexes | 5.5 | 5.7 | 4.0 | 4.2 | 3.8 | 4.7 | 5.8 | 5.4 | 5.8 | 3.9 | 3.9 | 3.8 | 4.8 | 5.8 |
Male | 7.1 | 7.4 | 5.2 | 5.5 | 4.9 | 5.9 | 7.5 | 7.0 | 7.5 | 5.1 | 4.8 | 4.9 | 6.0 | 7.5 | |
Female | 4.2 | 4.4 | 3.2 | 3.2 | 3.0 | 3.7 | 4.5 | 4.2 | 4.4 | 3.1 | 3.2 | 3.0 | 3.8 | 4.4 | |
Myeloma | Both Sexes | 3.3 | 3.0 | 6.2 | 3.2 | 1.6 | 2.7 | 3.0 | 3.2 | 3.0 | 5.7 | 3.0 | 1.6 | 2.7 | 3.0 |
Male | 4.1 | 3.9 | 7.5 | 3.6 | 2.0 | 3.4 | 3.9 | 4.0 | 3.9 | 6.9 | 2.9 | 2.0 | 3.3 | 3.9 | |
Female | 2.6 | 2.4 | 5.3 | 3.0 | 1.2 | 2.2 | 2.3 | 2.5 | 2.4 | 5.0 | 3.2 | 1.2 | 2.3 | 2.3 | |
Leukemia | Both Sexes | 6.4 | 6.7 | 5.4 | 4.0 | 3.6 | 4.6 | 6.8 | 6.2 | 6.6 | 5.1 | 3.3 | 3.7 | 4.7 | 6.7 |
Male | 8.6 | 8.9 | 7.0 | 5.1 | 4.8 | 5.8 | 9.1 | 8.2 | 8.7 | 6.6 | 4.7 | 5.0 | 5.8 | 8.8 | |
Female | 4.8 | 5.0 | 4.3 | 3.0 | 2.6 | 3.8 | 5.0 | 4.7 | 5.0 | 4.2 | 2.2 | 2.8 | 3.8 | 5.0 |
Footnotes:
a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
b The SEER 21 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts.
c Rates for American Indian/Alaska Native (AI/AN) are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
d Asian/Pacific Islander.
e Hispanic (Hisp) and White Non-Hispanic (W-NHisp) are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
- Statistic could not be calculated due to less than 16 cases in the time interval.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.